Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
4 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.

Radiotherapy with concurrent docetaxel beneficial in seniors with oesophageal cancer

02 Oct 2020

Radiotherapy with concurrent docetaxel is safe and effective in elderly patients with oesophageal cancer, regardless of baseline renal function, according to a study.

The study included 73 patients aged ≥76 years who were diagnosed with oesophageal squamous cell carcinoma. They received radiotherapy (60 Gy in 30 fractions) and concurrent docetaxel (10 mg/m2 weekly for six cycles), after which toxicity and treatment completion rates were retrospectively evaluated.

Of the patients, 49 showed declining renal function (creatinine clearance [Ccr] <60 mL/min; Ccr-L) while 24 had Ccr ≥60 mL/min (Ccr-H).

The overall response rates were 80 percent in the Ccr-L group and 75 percent in the Ccr-H. The 1-year and 3-year progression-free survival rates did not differ between the two groups: 42 percent and 28 percent in the Ccr-L group vs 38 percent and 18 percent in the Ccr-H group (p=0.45).

Likewise, overall survival rates at years 1 and 3 were similar: 65 percent and 39 percent in the Ccr-L group vs 62 percent and 22 percent in the Ccr-H group (p=0.2). The median survival time was 21 and 20 months, respectively (p=0.2).

The regimen was also similarly safe regardless of renal function. Grade 1 acute kidney injury occurred in 8 percent of patients each in the Ccr-L and the Ccr-H groups. There was no significant between-group difference in the number of patients with haematological or nonhaematological toxicities. None of the patients overall developed grade 4 or 5 toxicities.

Finally, treatment completion rates were comparable (88 percent in the Ccr-L group vs 92 percent in the Ccr-H group).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
Weight suppression appears to result in future onset of eating disorders characterized by dietary restriction or compensatory weight control behaviours, suggesting weight-suppressed women represent an at-risk group that may benefit from selective prevention programmes, a study has found.
4 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.